Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech US. The ACTIA Platform complements Cellular Origins’ existing approach and will accelerate and expand R&D efforts to further develop the Company’s robotic solution for automated cell therapy manufacturing, Constellation™.
Study shows differences between men and women’s reaction to stress
Does anyone still remember the initial phase of the Corona pandemic in 2020? When shops, restaurants, cinemas, and theatres remained closed. When meetings with friends
July 31, 2023